Placebo of Simvastatin

DRUG3 trials

Sponsors

Tanabe Pharma Corporation, Judit Pich

Conditions

Chronic Kidney DiseaseCirrhoses, LiverLiver Cirrhoses

Phase 2

Simvastatin Plus Rifaximin in Decompensated Cirrhosis

CompletedNCT03150459

Judit PichCirrhoses, Liver

Start: 2017-07-26End: 2018-03-12Updated: 2019-03-28

Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development

CompletedNCT03780673

Judit PichLiver Cirrhoses

Start: 2019-01-03End: 2022-12-01Updated: 2023-05-24

Phase 3

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

CompletedNCT00858637

Tanabe Pharma CorporationChronic Kidney Disease

Start: 2009-03-31End: 2010-03-31Updated: 2026-01-07

Related Papers

Simvastatin and Rifaximin in Decompensated Cirrhosis

JAMA2025-02-0522 citations

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease.

2023-01-2314 citations

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.

2019-10-1099 citations